Pieris Pharmaceuticals, Inc. (PIRS) Financials

PIRS Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2024 20.5 million 4.3 million
June 30, 2024 25.1 million 6.3 million
March 31, 2024 29.5 million 7.5 million
Dec. 31, 2023 38.7 million 11.9 million

PIRS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2024 146000 330000
June 30, 2024 -1.5 million 421000
March 31, 2024 -7.0 million 472000
Dec. 31, 2023 -19.7 million 451000

PIRS Net Income

No data available :(

PIRS Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2024 19.4 million - -
June 30, 2024 19.7 million - -
March 31, 2024 19.1 million - -
Dec. 31, 2023 26.4 million - -

PIRS Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2024 1.3 million
June 30, 2024 1.3 million
March 31, 2024 1.2 million
Dec. 31, 2023 1.2 million

PIRS Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2024 - 446000 3.6 million -
June 30, 2024 - 751000 3.4 million -
March 31, 2024 13000 1.2 million 4.1 million -
Dec. 31, 2023 13000 4.5 million 2.3 million -

PIRS Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2024 - -
June 30, 2024 - 751000
March 31, 2024 53000 -30000
Dec. 31, 2023 1.3 million 4.5 million

PIRS Revenue by Segment

Graph available only for paid members. Upgrade to see it.

PIRS

Price: $13.60

52 week price:
6.20
22.32

Earnings Per Share: -12.11 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 522800

Ebitda: -5.1 million

Market Capitalization: 21.9 million

Links: